Education
About Us
Working with TipRanks
Follow Us
Niagen Bioscience, Inc. (NAGE)
:NAGE
Top Page
Niagen Bioscience
(NASDAQ:NAGE)
Rating:73Outperform
Price Target:
$13.00
▲(12.95%Upside)
Positive Factors
Clinical Trials
A key clinical study in Parkinson's disease is expected to yield top-line results, potentially paving the way for new therapeutic uses of nicotinamide riboside.
Financial Performance
Revenue outperforms expectations, with Niagen Bioscience reporting $30.5M in top-line revenue, exceeding forecasted figures.
Market Expansion
Niagen IV broadens U.S. clinic footprint, poised for further rapid market uptake.
Negative Factors
Clinical Trial Risks
Key clinical study in Parkinson's disease remains slated to potentially yield top-line results in 1H25, which could significantly impact the company's prospects.
Regulatory Challenges
If the NO-PARK results prove positive, Niagen Bioscience is expected to explore the possibility of obtaining regulatory approval for a pharmaceutical-grade formulation of NR to treat Parkinson's disease, possibly through a spinout company or joint venture with a pharmaceutical company as partner.
Niagen Bioscience (NAGE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$922.79M
Dividend YieldN/A
Average Volume (3M)969.33K
Price to Earnings (P/E)66.6
Beta (1Y)1.02
Revenue Growth29.77%
EPS GrowthN/A
CountryUS
Employees104
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)0.07
Shares Outstanding78,769,660
10 Day Avg. Volume830,810
30 Day Avg. Volume969,334
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)11.30
Price to Sales (P/S)0.00
P/FCF Ratio44.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.33Price Target Upside-1.56% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Niagen Bioscience Business Overview & Revenue Model
Company DescriptionNiagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide.
How the Company Makes MoneyChromaDex makes money through the sale of its proprietary ingredient, Niagen, and its branded dietary supplement product, Tru Niagen. The company generates revenue primarily via direct-to-consumer sales through its e-commerce platform as well as through retail partnerships with major retailers and distributors. Additionally, ChromaDex licenses its ingredient technology to third parties, which further contributes to its revenue streams. The company also invests in research and development to support product efficacy claims, enhance brand credibility, and expand its market reach through scientific validation and partnerships with research institutions.
Niagen Bioscience Earnings Call Summary
Earnings Call Date:May 07, 2025
(Q1-2025)
| % Change Since: 36.21%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
Niagen Biosciences had a strong start to 2025 with significant revenue growth and net income achievement. The company saw impressive growth in e-commerce and ingredients, expanded its Niagen Plus availability, and improved gross margins. However, challenges persist with regulatory issues around NMN and misconceptions about NAD supplements. Additionally, there could be delays in obtaining study results for Parkinson's treatment. Overall, the positive achievements outweigh the challenges.Q1-2025 Updates
Positive Updates
Strong Revenue Growth
Niagen Biosciences reported $30.5 million in revenue for Q1 2025, marking a 38% year-over-year increase.
Net Income Achievement
The company achieved a net income of $5.1 million, a significant improvement from a net loss of $0.5 million in the previous year.
E-commerce and Ingredient Growth
E-commerce sales grew by 31% year-over-year, while the Niagen ingredient business saw a 95% increase.
Expansion of Niagen Plus
Niagen Plus is now available in nearly 600 clinics nationwide, with plans to expand to 1,000 by year-end.
Patent Portfolio Expansion
A new composition of matter patent was granted, expanding protection for all salt forms of nicotinamide riboside.
Improved Gross Margin
Gross margin improved to 63.4%, up from 60.7% the previous year.
Increased Cash Flow
Net cash provided by operations was $7.9 million, compared to $300,000 in the same period last year.
Raised Full-Year Revenue Outlook
The full-year top-line growth outlook was raised to 20% to 25% year-over-year.
Negative Updates
Regulatory Challenges with NMN
The FDA ruled NMN is not a lawful dietary ingredient, and Niagen supports enforcement against non-compliant NMN products.
Challenges with NAD Supplement Misconceptions
There are misconceptions about the effectiveness of NAD supplements, with three-quarters of NAD products on Amazon failing to meet label claims.
Potential Delays in Study Results
Results from the Phase 3 NOPARK study for Parkinson's disease may not be available for over a year due to the time needed for data analysis and publication.
Company Guidance
During the Niagen Biosciences' first quarter earnings call for fiscal 2025, several key financial metrics and strategic updates were highlighted. The company reported a revenue of $30.5 million, marking a 38% year-over-year increase, and a net income of $5.1 million. Cash generated from operations reached $7.9 million, with an ending cash balance of $55.6 million and no debt. The e-commerce sector was a significant driver of growth, contributing $16.8 million in net sales, a 31% increase from the previous year. The Niagen ingredient business also saw substantial growth, with sales reaching $8 million, a 95% year-over-year increase. Gross margin improved to 63.4%, up from 60.7% the previous year. The company's strategic initiatives include expanding the availability of Niagen Plus, now offered in nearly 600 clinics, and advancing research and regulatory engagements for pharmaceutical applications of NR (nicotinamide riboside), particularly in Parkinson's disease and ataxia-telangiectasia. The company also raised its full-year revenue growth outlook to 20%-25% year-over-year, reflecting confidence in the expanding NAD market.Niagen Bioscience Financial Statement Overview
Summary
Chromadex demonstrates significant financial improvement with a shift to profitability and enhanced cash flow generation. The balance sheet is strong with low leverage, but declining revenue trends pose a risk to long-term growth. Addressing revenue growth challenges will be key.Income Statement
Chromadex shows a substantial recovery in net income from a loss of $4.94M in 2023 to a profit of $8.55M in 2024, indicating strong profitability improvements. However, revenue decreased from $83.57M in 2023 to $61.59M in 2024, resulting in a negative revenue growth rate, which is a concern. The company achieved a positive EBIT margin, shifting from a negative margin in the previous year, reflecting improved operational efficiency.65
Positive
Balance Sheet
The company has a strong equity position with a debt-to-equity ratio of 0.06, indicating low leverage. The equity ratio increased to 67.5% in 2024, up from 51.8% in 2023, highlighting a solid capital structure. Return on equity improved significantly with positive net income, reflecting enhanced shareholder value. The balance sheet is robust, but a reduction in total revenue could impact future stability.72
Positive
Cash Flow
Chromadex's free cash flow increased significantly from $6.97M in 2023 to $11.95M in 2024, showcasing strong cash generation capabilities. The operating cash flow to net income ratio is healthy, indicating efficient conversion of income into cash. Despite a decrease in investing cash flow, the strong free cash flow growth signals good financial health.78
Positive
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 99.60M | 83.57M | 72.05M | 67.45M | 59.26M | Gross Profit |
| 61.59M | 50.78M | 42.80M | 41.49M | 35.27M | EBIT |
| 7.73M | -5.60M | -18.63M | -27.07M | -19.85M | EBITDA |
| 9.21M | -3.89M | -16.74M | -25.45M | -18.34M | Net Income Common Stockholders |
| 8.55M | -4.94M | -16.54M | -27.13M | -19.93M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 44.51M | 27.17M | 20.29M | 28.02M | 16.50M | Total Assets |
| 68.28M | 54.96M | 54.06M | 57.84M | 38.36M | Total Debt |
| 2.65M | 3.28M | 4.26M | 4.70M | 1.64M | Net Debt |
| -41.86M | -23.90M | -16.03M | -23.32M | -14.86M | Total Liabilities |
| 22.18M | 26.51M | 25.39M | 26.11M | 21.93M | Stockholders Equity |
| 46.09M | 28.46M | 28.67M | 31.73M | 16.42M |
| Cash Flow | Free Cash Flow | |||
| 11.95M | 6.97M | -15.43M | -24.57M | -10.74M | Operating Cash Flow |
| 12.11M | 7.12M | -15.10M | -24.16M | -10.60M | Investing Cash Flow |
| -143.00K | -143.00K | -334.00K | -409.00K | -165.00K | Financing Cash Flow |
| 5.37M | -90.00K | 7.65M | 36.09M | 8.65M |
Niagen Bioscience Technical Analysis
Positive
11.51
Price Trends
8.41
Positive
7.36
Positive
6.12
Positive
Market Momentum
0.90
Negative
69.20
Neutral
85.46
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAGE, the sentiment is Positive. The current price of 11.51 is above the 20-day moving average (MA) of 10.53, above the 50-day MA of 8.41, and above the 200-day MA of 6.12, indicating a bullish trend. The MACD of 0.90 indicates Negative momentum. The RSI at 69.20 is Neutral, neither overbought nor oversold. The STOCH value of 85.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NAGE.
Niagen Bioscience Risk Analysis
Niagen Bioscience disclosed 55 risk factors in its most recent earnings report. Niagen Bioscience reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Any failure by clinics administering Niagen Plus products could adversely affect our brand and reputation. Q4, 2024
2.
Failure by outsourcing facilities that produce pharmaceutical-grade Niagen to adequately perform their obligations could harm our business or financial results. Q4, 2024
3.
We may not be able to monetize our products for use in pharmaceuticals through partnerships, licensing, or other arrangements, and we may not receive regulatory approval to commercialize a pharmaceutical product. Q4, 2024
Niagen Bioscience Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $922.79M | 66.65 | 33.47% | ― | 29.77% | ― | |
55 Neutral | $574.38M | ― | -37.13% | ― | -38.14% | 29.69% | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% | |
50 Neutral | $460.27M | ― | -1.44% | ― | 1.98% | 63.69% | |
47 Neutral | $562.80M | ― | -45.75% | ― | -11.76% | -15.82% | |
39 Underperform | $480.43M | ― | ― | -25.10% | -7.06% | ||
33 Underperform | $523.29M | ― | -71.44% | ― | ― | 19.94% |
* Healthcare Sector Average
Performance Comparison
NAGE
Niagen Bioscience
11.51
8.31
259.69%
SVA
Sinovac Biotech
6.47
0.00
0.00%
BCYC
Bicycle Therapeutics
8.50
-14.54
-63.11%
OPT
Opthea Limited Sponsored ADR
3.20
0.83
35.02%
MRVI
Maravai Lifesciences Holdings
2.17
-6.44
-74.80%
SANA
Sana Biotechnology
2.55
-4.43
-63.47%
Niagen Bioscience Corporate Events
Business Operations and StrategyFinancial Disclosures
Niagen Bioscience Reports Strong Q1 2025 Financial Results
Positive
May 7, 2025
On May 7, 2025, Niagen Bioscience, Inc. reported its financial results for the first quarter of 2025, revealing a significant year-over-year increase in net sales by 38% to $30.5 million, driven by strong demand for its Tru Niagen® and Niagen® ingredient products. The company achieved a gross margin of 63.4% and net income of $5.1 million, marking a substantial improvement from the previous year. Additionally, Niagen Bioscience announced an increased full-year outlook for 2025, expecting net sales growth between 20% and 25%, and highlighted its strategic rebranding and expansion of its NAD+ precursor patent portfolio, reinforcing its leadership in the healthy aging sector.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.